- Home
- MGTX vs MGNX Comparison
MGTX vs MGNX Comparison
Compare MGTX & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- MGNX
- Stock Information
- Founded
- MGTX 2015
- MGNX 2000
- Country
- MGTX United States
- MGNX United States
- Employees
- MGTX N/A
- MGNX N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- MGTX Health Care
- MGNX Health Care
- Exchange
- MGTX Nasdaq
- MGNX Nasdaq
- Market Cap
- MGTX 302.6M
- MGNX 263.1M
- IPO Year
- MGTX N/A
- MGNX 2013
- Fundamental
- Price
- MGTX $4.27
- MGNX $3.36
- Analyst Decision
- MGTX Strong Buy
- MGNX Buy
- Analyst Count
- MGTX 2
- MGNX 12
- Target Price
- MGTX $22.50
- MGNX $8.89
- AVG Volume (30 Days)
- MGTX 160.3K
- MGNX 658.4K
- Earning Date
- MGTX 11-12-2024
- MGNX 11-04-2024
- Dividend Yield
- MGTX N/A
- MGNX N/A
- EPS Growth
- MGTX N/A
- MGNX N/A
- EPS
- MGTX N/A
- MGNX N/A
- Revenue
- MGTX $8,122,000.00
- MGNX $41,018,000.00
- Revenue This Year
- MGTX $133.83
- MGNX $110.57
- Revenue Next Year
- MGTX $655.34
- MGNX N/A
- P/E Ratio
- MGTX N/A
- MGNX N/A
- Revenue Growth
- MGTX 26.87
- MGNX N/A
- 52 Week Low
- MGTX $3.49
- MGNX $3.14
- 52 Week High
- MGTX $7.60
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- MGTX 52.96
- MGNX 42.62
- Support Level
- MGTX $3.86
- MGNX $3.33
- Resistance Level
- MGTX $4.39
- MGNX $3.79
- Average True Range (ATR)
- MGTX 0.19
- MGNX 0.24
- MACD
- MGTX 0.05
- MGNX 0.05
- Stochastic Oscillator
- MGTX 77.78
- MGNX 28.33
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).